In medical news:

The FDA said in a statement that it is issuing a critical policy document that addresses how a bulk substances list for compound drugs will be formulated, and what bulk drug substances the outsourcing facilities can use to compound drugs. The draft guidance is one part of a policy that began in January, when FDA released its compounding policy priorities plan. The plan is comprised of a series of draft and final guidance documents, proposed and final rules, and a revised draft memorandum of understanding (MOU) between the FDA and states.

Read more here.

Leave a Comment

Your email address will not be published. Required fields are marked *